46 results about "Zonulin" patented technology

The present invention relates to the fields of medicine and cosmetology, and discloses a cell active peptide composition that promotes the regeneration of multi-type collagen structural proteins, its preparation method, and its application in medicine and cosmetology. The composition uses raw materials such as tripeptide-10 citrulline, hexapeptide-9, hydrolyzed sodium hyaluronate, γ-aminobutyric acid, decarboxylated carnosine hydrochloride, acetyl tetrapeptide-3, acetyl tetrapeptide-11, palmitoyl dipeptide-7, and palmitoyl pentapeptide-4. The composition can promote the coordinated expression of skin type I, type III, type IV, type VII, type XVII collagen, fibronectin, elastin, and glycosaminoglycans; prevent collagen cross-linking, maintain triple helix structure, and inhibit collagen degradation. Applied to dermatology and cosmetology, it can accelerate the regeneration of structural proteins such as skin collagen, repair skin damage, reduce wrinkles such as crow's feet, tear groove lines, nasolabial folds, and under-eye lines, solve the skin aging problem caused by the loss of structural proteins such as collagen, and improve skin elasticity and firmness.

Provided are antibodies that include amino acid sequences of SEQ ID NOs: 2, 4, and 6-12, or amino acid sequences that are about 95% identical thereto, and fragments thereof. Also provided are scFv peptides that include a VH segment having a first amino acid sequence of amino acids 4-113 of any one of SEQ ID NOs: 2 and 8-12, a VL segment having a second amino acid sequence having amino acids 113-237 of SEQ ID NOs. 2 and 8-12, or both; nucleic acids encoding the same; methods for using the same to detect and / or target conformational states of FN in samples; methods for treating diseases and / or disorders and / or for meliorating at least one symptom of consequence of a disease or disorder associated with abnormal expression of a force-induced conformational state of FN in subjects; and methods for screening for compounds having selective binding activities for conformational states of FN.

The present invention relates to a composition comprising the compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of fibrotic diseases. The composition according to the present invention inhibits the expression of collagen type 1 (COL1A1) or fibronectin and thus can be advantageously used as a composition for the prevention or treatment of fibrotic diseases.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

Provided herein are methods for improving glycemic control in a human patient, methods for treating, preventing or reducing overweight or obesity and related co-conditions, and methods for treating or preventing type II diabetes mellitus by administering a polypeptide to the patient, the polypeptide comprises a fibronectin type III tenth (10Fn3) domain that binds to a myostatin. In some embodiments, the polypeptides are administered according to a specific clinical dosing regimen (e.g., at a specific dose and according to a specific time interval) (or for administration according to the regimen).

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

Provided are antibodies that include amino acid sequences of SEQ ID NOs: 2, 4, and 6-12, or amino acid sequences that are about 95% identical thereto, and fragments thereof. Also provided are scFv peptides that include a VH segment having a first amino acid sequence of amino acids 4-113 of any one of SEQ ID NOs: 2 and 8-12, a VL segment having a second amino acid sequence having amino acids 113-237 of SEQ ID NOs. 2 and 8-12, or both; nucleic acids encoding the same; methods for using the same to detect and / or target conformational states of FN in samples; methods for treating diseases and / or disorders and / or for meliorating at least one symptom of consequence of a disease or disorder associated with abnormal expression of a force-induced conformational state of FN in subjects; and methods for screening for compounds having selective binding activities for conformational states of FN.

The application discloses a recombinant humanized collagen composition for resisting HPV infection and a preparation method thereof. The composition comprises the following components in percentage by mass: 30-45% of a recombinant humanized collagen fusion protein, 30-40% of probiotics and 20-35% of glycogen. The recombinant humanized collagen fusion protein comprises, from N-terminal to C-terminal, a recombinant humanized collagen fragment and a human fibronectin fragment connected in sequence. The recombinant humanized collagen fragment and the human fibronectin fragment are connected by a linker. The recombinant humanized collagen fusion protein in the composition can promote the adhesion and colonization of the probiotic composition to the vaginal epithelial cells, rapidly improve the microbial environment of the vagina and effectively enhance the resistance of the vagina to harmful bacteria and viruses.

The present invention discloses a recombinant type VII collagen protein, Pro.C7, whose amino acid sequence is shown in any one of SEQ ID NOs. 1-8. Also disclosed are its encoding gene, expression vector, host bacteria, preparation method, and application. The present invention designs recombinant human type VII collagen based on a partial sequence of human type VII collagen. The protein is expressed in prokaryotes, and the expression system is mature. The purified protein has been experimentally verified to be non-cytotoxic. By organizing laminin, it promotes fibroblast migration and cytokine secretion, participates in skin damage and repair, and can be used as a biomaterial in cosmetic products, among other applications.

The invention relates to bacillus subtilis as well as a construction method and application thereof, and the bacillus subtilis is a gram-positive bacterium from soil, also belongs to one kind of probiotics, and has multiple benefits to a human body. The Irisin is a novel muscle factor which is generated by shearing a transmembrane fibronectin type III domain protein 5 (fibronectin type III domain-conforming protein 5, FNDC5) through a proteolytic enzyme, and has the effects of alleviating obesity, improving insulin resistance, resisting inflammation and the like. According to the invention, a strain of bacillus subtilis capable of expressing human active irisin is constructed, and meanwhile, a probiotic oral embedding method is provided, so that the in-vivo activity and effect of the bacillus subtilis are improved. The expression strain not only can express and produce the tectoridin protein with activity and without endotoxin, but also can exert the activity of probiotics through oral administration after embedding.

The invention belongs to the technical field of application of biomarker detection kits, and particularly relates to application of a kit for detecting fibronectin in evaluating the intestinal injury state, and the kit comprises an antibody specifically binding to fibronectin; the kit is used for detecting the fibronectin content in an excrement sample, and the intestinal injury state is evaluated based on the fibronectin content. In conclusion, the invention provides the application of the kit for detecting fibronectin, which is based on the excrement sample, is accurate in early stage and is superior to the existing marker, in evaluating the intestinal injury state.

Compositions and methods use one or more feline circulating proteins as markers for early chronic kidney disease (CKD) to diagnose and / or treat CKD. A method of diagnosing chronic kidney disease (CKD) in a feline can include measuring an amount of each of at least one circulating protein from the feline. The at least one circulating protein is one or more of adiponectin (ADIPOQ), antibacterial peptide (CAMP), kinetin-like protein (KIF12), plasma retinol binding protein (RBP4), Ig-like domain containing protein (ZKSCAN1), blood coagulation factor X (F10), fibronectin (FN1), and mixtures thereof. The method further comprises comparing the amount of each of the at least one circulating protein from the feline to a respective predetermined value or a respective predetermined range. The method further comprises diagnosing the feline as having or not having early CKD based on the comparison.

The invention belongs to the technical field of biology, and discloses a composition for promoting proliferation of human immortalized keratinocytes and application of the composition. The inventor finds that the collagen, the fibronectin, the allantoin and the kava pepper leaf / root / stem extract have a good synergistic effect, proliferation of HaCaT cells can be remarkably promoted, and the composition can accelerate repair of damaged skin barriers. Therefore, the invention has a good application prospect in skin care products.

This invention belongs to the field of biomedicine, specifically relating to the application of APOL2 (Apolipoprotein L2) inhibitors in the preparation of products for treating liver fibrosis. The inventors isolated a series of natural tetrodopane-type diterpenes from *Euphorbia pekinensis*, a plant in the Euphorbiaceae family. Anti-liver fibrosis-related activity tests on this series of diterpenes revealed that they significantly inhibited the expression of fibronectin, type I collagen, and α-smooth muscle actin in LX-2 cells. In animal studies, their therapeutic effect was superior to that of pirfenidone, a phase II clinical trial drug for treating liver fibrosis, and they showed no significant toxicity. Mechanistic studies showed that TD1 is an APOL2 inhibitor, and knocking out APOL2 protein in vivo can alleviate the progression of liver fibrosis. In summary, this series of tetrodopane-type diterpenes, especially TD1, shows promise as a candidate drug for treating liver fibrosis and provides a new target for researching novel drugs for treating liver fibrosis.

The application discloses a lignan compound and a preparation method and application thereof, and relates to the technical field of medicines. The application specifically relates to four lignan small-molecule compounds with the same planar structure, which are separated from amber, and include two pairs of enantiomers (+)-6 / (-)-6 and (+)-7 / (-)-7. The compound structures are as follows: In a renal fibrosis model experiment, the lignan compound provided by the application can inhibit the expression of proteins related to renal fibrosis, such as alphaSMA protein, type I collagen protein and fibronectin, in NRK-52E cells induced by transforming growth factor beta 1, which indicates that the lignan compound provided by the application has the use of preparing medicines for preventing and treating renal fibrosis.

Provided is a polypeptide that binds specifically to an artificial low molecular weight ligand. This polypeptide, in which a BC loop of a fibronectin type III domain scaffold contains an amino acid sequence represented by the following formula (1): X1aX1bX1cX1dX1eDX1fX1gD (wherein X1a is A, S, or R, X1b and X1c are each independently an arbitrary amino acid, X1d is N, H, W, or Y, and X1e to X1g are each independently an arbitrary amino acid), and an FG loop contains an amino acid sequence represented by the following formula (2): X2aX2bX2cX2dX2eKX2fX2gX2hX2i (wherein X2a and X2b are each independently an arbitrary amino acid, X2c is G, M, N, Y, or W, X2d is an arbitrary amino acid, X2e is Y, F, P, W, V, or A, X2f is W, Y, V, F, or S, X2g is W, L, V, or M, X2g if V, C, G, or A, and X2i is an arbitrary amino acid), binds specifically to an artificial low molecular weight ligand such as 1-(4-hydroxyphenyl)-3-phenylurea (HPPU) or a derivative thereof.

A method for preparing a bionic injectable polypeptide hydrogel is provided. The hydrogel is formed using a brain extracellular matrix laminin-derived peptide DDIKVAV modified with 9-fluorenylmethoxycarbonyl (Fmoc) (Fmoc-DDIKVAV) and an immunostimulatory peptide FTKPRF modified with Fmoc (Fmoc-FTKPRF) as hydrogel monomers. These monomers further utilize non-covalent bond forces such as hydrogen bonds, hydrophobic interactions, and x-x stacking to co-assemble into a hydrogel within a short time at 37° C. The bionic hybrid polypeptide hydrogel is injectable and can serve as a drug reservoir implanted into cavities formed after tumor surgery. The drugs loaded in the hydrogel are slowly released at a stable and controlled rate and appropriate concentration within the post-surgical cavity, thereby effectively killing residual tumor cells while avoiding the toxic side effects of systemic drug administration.

This invention relates to the field of pharmaceutical technology, specifically to the application of morin A in the preparation of drugs for the prevention and treatment of pulmonary fibrosis. This invention discovers a novel use for morin A, a monomeric component of traditional Chinese medicine, which can be applied to the prevention and treatment of pulmonary fibrosis. By reducing the transcriptional and protein expression levels of fibronectin, α-actin, and type I collagen in fibroblasts, it inhibits the differentiation of fibroblasts into myofibroblasts, thereby slowing the progression of pulmonary fibrosis and providing a new treatment strategy for pulmonary fibrosis. Experimental results show that lung injury and fibrosis were significantly reduced in mice treated with intraperitoneal injections of 10 mg / kg and 20 mg / kg morin A. Furthermore, experiments on human primary fibroblasts also demonstrate that morin A can significantly reduce the protein expression levels of type I collagen, fibronectin, and α-actin in TGF-β1-stimulated human primary fibroblasts.

A method for diagnosing facioscapulohumeral muscular dystrophy (FSHD) using one or more biomarkers is provided. More particularly, provided is a method for diagnosing FSHD in a subject, the method comprising detecting the presence of a biomarker or change in level of a biomarker in a biological sample from the subject, wherein the biomarker is wherein the biomarker is mannose binding lectin 2 (MBL2), junction plakoglobin (JUP), desmoplakin (DSP), tetranectin (CLEC3B), complement component 7 (C7), complement component 9 (C9), tenascin C (TNG), lumican (LUM), phosphatidylinositol-glycan-specific phospholipase D (GPLD1 ), complement component 4 binding protein, beta chain (C4BPB), carnosine dipeptidase (CNDP1), or immunoglobulin kappa variable 2-30 (IGKV2-30), or a combination of any two or more of MBL2, JUP, DSP, CLEC3B, C7, C9, TNG, LUM, GPLD1, C4BPB, CNDP1, or IGKV2-30. In some aspects, when the change in level of the biomarker is an increase in the level of MBL2, JUP, DSP, CLEC3B, C7, C9, TNG, and / or LUM, or a combination of any thereof, the subject is diagnosed as having FSHD. In some aspects, when the change in level of the biomarker is a decrease in the level of GPLD1, C4BPB, CNDP1, and / or IGKV2-30, or a combination of any thereof, the subject is diagnosed as having FSHD. Also provided is a method for determining efficacy of a therapeutic treatment for FSHD in a subject, the method comprising measuring the level of a biomarker in a biological sample from the subject before and after the treatment, and determining that the treatment is effective in treating FSHD if the level of the biomarker is decreased or increased relative to a reference level or to the level of the biomarker in the sample from the subject before treatment, wherein when the biomarker is mannose binding lectin 2 (MBL2), junction plakoglobin (JUP), desmoplakin (DSP), tetranectin (CLEC3B), complement component 7 (C7), complement component 9 (C9), tenascin C (TNG), or lumican (LUM), or a combination of any two or more of MBL2, JUP, DSP, CLEC3B, C7, C9, TNG, or LUM, the treatment is effective when the level of the biomarker decreases, or wherein when the biomarker is phosphatidylinositol-glycan-specific phospholipase D (GPLD1), complement component 4 binding protein, beta chain (C4BPB), carnosine dipeptidase (CNDP1), or immunoglobulin kappa variable 2-30 (IGKV2-30), or a combination of any two or more of GPLD1, C4BPB, CNDP1, or IGKV2-30, the treatment is effective when the level of the biomarker increases. In various aspects, the method further comprises treating the subject diagnosed with FSHD.

Fusion polypeptides including at least one Fc binding domain linked to at least one integrin binding domain are provided. In some embodiments, the at least one Fc binding domain is one or more Fc binding domains from Protein A, Protein G, or Protein Z and the at least one integrin binding domain comprises one or more fibronectin type III domains (for example repeats 12-14 of fibronectin type III domains and optionally the connecting segment of fibronectin). Protein complexes including the polypeptide and one or more antibodies are also provided. Methods of using the polypeptide and / or polypeptide:antibody complex are provided, including treating a subject with a tumor, inducing an immune response to a tumor, and / or targeting an antibody to a tumor cell.

Methods for the treatment and prevention of laminopathies and diseases characterised by hyperlipidemia through LING complex inhibition are disclosed. In particular, LING complex disruption by expression of dominant-negative LING complex proteins alleviates pathophysiology in Lmna mutation-associated muscular dystrophy, progeria, and dilated cardiomyopathy. In addition, LING complex disruption by expression of dominant-negative LING complex proteins also alleviates pathophysiology in mouse models of atherosclerosis and familial hypercholesterolemia.

The present invention relates to a fusion protein that specifically binds to the extradomain B of fibronectin (EDB-FN) and transforming growth factor β (TGF-β), and use thereof; and, more specifically, to a fusion protein comprising a polypeptide that specifically binds to EDB-FN and a polypeptide that specifically binds to TGF-β, and use thereof.The fusion protein according to the present invention fixes TGF-β, which plays an important role in antitumor immune responses, to the extracellular matrix, in order to localize the inhibition of TGF-β directly in the tumor microenvironment and ensure a local rather than systemic effect, thus showing an excellent anticancer effect in all carcinomas, including pancreatic cancer, in which the usual TGF-β inhibitors do not act due to the rigidity of the extracellular matrix, so that it can be used effectively for the prevention or treatment of cancer.

An anticancer peptide conjugate is described that comprises the following formula: P-L-A wherein: P is a peptide that includes an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or variants thereof in which one or more L-amino acids have been replace with a corresponding D-amino acid; A is an antitumor agent; and L is an optional linker that covalently links the peptide to the antitumor agent, and pharmaceutically acceptable salts thereof. Methods of using the anticancer peptide conjugates to treat cancer are also described.

The present invention provides antigen-binding proteins capable of binding to Nectin-4 polypeptides conjugated to chemotherapeutic agents, for use in increasing sensitivity of tumors to the chemotherapeutic agents, for use in the treatment of cancers characterized by Nectin expressing tumor cells. In one embodiment, the present invention provides conjugates of an anti-Nectin-4 antibody to a camptothecin analogue, such as exatecan or SN-38, through a cleavable linker.

The present application relates to a kind of laminin or its specific fragment polypeptide, the complex formed by non-covalent adsorption immunological factor with it and its application in biomaterials.38 polypeptides screened by the present application. One or more of the complete laminin containing the polypeptide screened by the present application, or complete fibronectin is used as carrier protein, and is mixed with biomaterial base, immunological factor etc. to make complex, because there is non-covalent adsorption between carrier protein and immunological factor, immunological factor can be biomimetic adsorption carried on the material combined with carrier protein. The product containing the complex of the present application can automatically dissociate and release immunological factor in neutral environment and maintain the slow release for several days.Moreover, the product made of the complex of the present application can avoid activating the immune response of the implant, solve the problem that transgenic expression vector enters the patient's body and easily induces intense immune response, difficult to realize secondary administration etc.

Disclosed are compositions, compounds, and methods relating to peptides that can target and home to cancer, tumors, and extracellular matrix. This is based on the discovery of peptides that can specifically bind to fibronectin extra domain B (FN-EDB), tenascin-C C domain (TNC-C), or both.